About this course
The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide, accounting for around half a billion cases in 2021 alone. In addition, the risk factors for both T2DM and heart failure (HF) commonly overlap, with a magnified risk of HF in individuals with T2DM. This warrants further research into the risk assessment of HF. As demonstrated by various clinical studies, this module will focus on the role of NT-proBNP as a predictive biomarker for HF in individuals with T2DM.
Upon completion of this module, participants should be able to:
- Acknowledge the burden of T2DM and its association with Cardiovascular Disease (CVD)
- Assess the risk of CVD using validated risk-score tools.
- Understand the role of NT-proBNP as a biomarker for HF in patients with T2DM
- Be familiar with the guidelines on the use of NT-proBNP as a diagnostic tool for HF in T2DM
- Prevalence and burden of T2DM and its association with HF
- Assessing HF risk in individuals with T2DM
- Using NT-proBNP as a biomarker for HF in T2DM
- Guidelines on the use of NT-proBNP in T2DM